000230.KS
Ildong Holdings Co., Ltd.
KSC · Healthcare · Drug Manufacturers - Specialty & Generic · KR
KRW 6,300.00
−3.82%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 607.2B | 590.9B | 657.6B | 638.4B | 675.5B |
| Cost of Revenue | 377.7B | 375.7B | 424.8B | 439.6B | 436.4B |
| Gross Profit | 229.5B | 215.1B | 232.8B | 198.9B | 239.1B |
| Operating Expenses | |||||
| R&D Expense | 27.0B | 35.5B | 55.9B | 108.0B | 119.4B |
| SG&A Expense | 66.6B | 69.0B | 71.3B | 168.4B | 200.2B |
| General & Admin Expense | 10.5B | 12.2B | 15.7B | 117.8B | 120.2B |
| Selling & Marketing Expense | 56.0B | 56.8B | 55.5B | 50.6B | 80.1B |
| Other Expenses | 109.4B | 98.5B | 108.0B | 2.1B | 17.7B |
| Total Operating Expenses | 203.0B | 203.0B | 235.2B | 278.4B | 337.4B |
| Cost and Expenses | 583.2B | 576.0B | 660.0B | 718.0B | 773.8B |
| Operating Income (EBIT) | 26.2B | 12.1B | (2.4B) | (79.6B) | (98.3B) |
| Non-Operating | |||||
| Interest Income | 661.5M | 666.5M | 1.1B | 1.4B | 1.7B |
| Interest Expense | 13.7B | 23.2B | 34.1B | 30.1B | 17.2B |
| Net Interest Income | (13.1B) | (22.5B) | (33.0B) | (28.7B) | (15.5B) |
| Other Non-Op Income/Expense | 27.3B | 15.2B | 55.9B | (52.5B) | (74.5B) |
| Non-Operating Income (excl Interest) | (41.1B) | (38.4B) | (90.1B) | 22.4B | 57.3B |
| EBT (Pre-Tax Income) | 53.3B | 30.3B | 53.5B | (132.1B) | (173.0B) |
| Income Tax Expense | 10.4B | 11.1B | (2.1B) | (13.3B) | 21.6B |
| Bottom Line | |||||
| Net Income | 21.7B | 10.9B | 63.0B | (59.6B) | (102.4B) |
| Earnings from Cont. Ops | 42.9B | 19.3B | 55.6B | (118.8B) | (194.5B) |
| Earnings from Discont. Ops | 412.1M | 2.3B | — | — | 535.5K |
| Bottom Line Net Income | 21.7B | 10.9B | 63.0B | (59.6B) | (102.4B) |
| Per Share | |||||
| Basic EPS | ₩2,653 | ₩967 | ₩5,583 | (₩5,277) | (₩9,064) |
| Diluted EPS | ₩2,653 | ₩967 | ₩5,063 | (₩5,277) | (₩9,064) |
| Revenue Per Share | ₩7,103 | ₩51,204 | ₩58,233 | ₩56,540 | ₩59,825 |
| Shares | |||||
| Basic Shares Outstanding | 85.5M | 11.5M | 11.3M | 11.3M | 11.3M |
| Diluted Shares Outstanding | 85.5M | 11.5M | 12.9M | 11.3M | 11.3M |
| Profitability Metrics | |||||
| EBITDA | 53.2B | 41.5B | 124.4B | (64.0B) | (116.3B) |
| D&A | 28.1B | 29.3B | 36.5B | 37.9B | 39.4B |
| EBIT | 25.1B | 12.1B | 87.6B | (102.0B) | (155.7B) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026